论文部分内容阅读
心先安是环磷酸腺苷葡甲胺的商品名称,属于环腺苷酸类化合物。药理试验和生化研究表明:心先安具有增强心肌收缩功能,降低外周血管阻力,增加冠脉流量,改善心肌缺血,降低心肌耗氧量等作用。由于其效果显著,毒副作用小,且有抑制磷酸二酯酶的作用,因此优于其他环腺苷酸类药物。 心先安于1978年底由徐州医学院原制药厂试验室首次合成,并进行了理化性质、药理作用和质量标准等研究。1979年6月开始在徐州医学院附院进行小规模的临床探索,
Cardioprotection is a commercial name of cyclic adenosine monophosphate, belonging to cyclic adenosine monophosphate. Pharmacological tests and biochemical studies have shown that: Xian Xian have to enhance myocardial contractility, reduce peripheral vascular resistance, increase coronary flow, improve myocardial ischemia, reduce myocardial oxygen consumption and so on. Because of its significant effect, small side effects, and inhibit the role of phosphodiesterase, it is superior to other cyclic adenosine drugs. The heart of Xian in the end of 1978 by the Xuzhou Medical University, the original pharmaceutical laboratory synthesis for the first time, and carried out the physical and chemical properties, pharmacological effects and quality standards and other research. 1979 June began in Xuzhou Medical College Affiliated Hospital for small-scale clinical exploration,